anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BWLI-College is a multicomponent behavioral weight loss intervention to reduce weight through diet, physical activity, and behavioral modifications designed to be responsive to emerging adult preferences. It will be delivered in a hybrid format with in-person and remotely-delivered asynchronous sessions. As presently designed, the intervention will last 10 weeks, though this may change with refinement.
Duchenne and Becker muscular dystrophies, caused by pathogenic variants in DMD, are the most common inherited neuromuscular conditions in childhood. These diseases follow an X-linked recessive inheritance pattern, and mainly males are affected. The most prevalent pathogenic variants in the DMD gene are copy number variants (CNVs), and most patients achieve their genetic diagnosis through Multiplex Ligation-dependent Probe Amplification (MLPA) or exome sequencing. Here, we investigated a female patient presenting with muscular dystrophy who remained genetically undiagnosed after MLPA and exome sequencing. RNA sequencing (RNAseq) from the patient's muscle biopsy identified an 85% reduction in DMD expression compared to 116 muscle samples included in the cohort. A de novo balanced translocation between chromosome 17 and the X chromosome (t(X;17)(p21.1;q23.2)) disrupting the DMD and BCAS3 genes was identified through trio whole genome sequencing (WGS). The combined analysis of RNAseq and WGS played a crucial role in the detection and characterisation of the disease-causing variant in this patient, who had been undiagnosed for over two decades. This case illustrates the diagnostic odyssey of female DMD patients with complex structural variants that are not detected by current panel or exome sequencing analysis.
The liposomal preparation proposed is suitable for use in pharmaceutics and medicine, in particular as a carrier for drugs, vaccines, diagnostic agents and vectors. Its production and use are also disclosed. The liposomes in the preparation proposed are exclusively, or to by far the greater part, unilamellar liposomes of small to medium size, preferably 10 t0 300 nm in diameter, with a closely packed vesicular structure. A high proportion, preferably at least 20 %, of the active substance is included in the preparation in encapsulated form. The preparation can be used directly as a depot of the encapsulated substance, or after stepwise dilution by addition of an aqueous solution. The preparation is produced by mixing a lipid or lipids, water and the active substance to be incorporated, and subsequently removing the solvents by evaporation and dispersal in water, followed by single or multiple high-pressure homogenization (at the most 50 times) at a pressure between 50 and 1600 bar (5-160 MPa) and, optionally, freeze/thaw treatment. The preparation is then converted into a free-flowing dispersion which is extruded through filters with a pore size of 0.1 to 1 νm.
INTRODUCTION: Hypoxia training is mandatory for military pilots, but variability in hypoxia symptoms challenges the training. In a previous study we showed that 64% of pilots recognized hypoxia faster in their second normobaric hypoxia session conducted 2.4 yr after the first. Our aim here was to evaluate whether a third session conducted 5.0 yr after the first would provide further benefit.
METHODS: This study was conducted under normobaric conditions in a tactical F/A-18C Hornet simulator in three sessions in which the pilots performed visual identification missions and breathed 21% oxygen in nitrogen. The breathing gas was changed to a hypoxic mixture containing either 8%, 7%, or 6% oxygen in nitrogen without the pilot's knowledge. Data were collected from 102 military pilots. The primary outcome was the time taken for initial identification of hypoxia symptoms.
RESULTS: Hypoxia symptoms were recognized on average in the first session in 8% oxygen in 100 s, 7% oxygen in 90 s, and 6% oxygen in 78 s; in the second in 87 s, 80 s, and 71 s, respectively; and in the third in 79 s, 67 s, and 64 s, respectively. In 2 sessions 20 pilots and in each 3 training sessions 3 pilots had slow recognition times.
DISCUSSION: Hypoxia symptom recognition improved the further the repeated normobaric hypoxia training went. More emphasis should be put on the 23% group of slow hypoxia symptom recognizers and more customized hypoxia training for them should be offered. Leinonen AM, Varis NO, Kokki HJ, Leino TK. Normobaric hypoxia symptom recognition in three training sessions. Aerosp Med Hum Perform. 2024; 95(10):758-764.
PURPOSE:To obtain an admixture for cosmetics, showing an entirely new opal- like color, having a high-grade visual appearance and excellent in optical stability of the opal-like color by blending a silica fine powder prepared by deionization of silica sol. CONSTITUTION:This cosmetic is obtained by blending silica fine particles, especially having <=0.70mum average particle size and <=15% variation coefficient of particle diameter in an amount of <=20vol.% on SiO2 base. As the silica fine particle, one having <=560muS/cm conductivity is preferably used. In this cosmetic, a silica suspension prepared by dispersing the silica fine particles in water or an organic solvent and then deionizing the resultant silica sol according to the ion-exchange treatment (The treatment is carried out till the conductivity of the silica sol reaches about <=560muS/cm) and exhibiting a stabilized colloidal dispersion state is used. Thereby, a color peculiar to opal is shown. The silica suspension is useful as an admixture for a toilet water, a milky lotion, etc.
Study participants will be assigned to either Group 1 (n=10) or Group 2 (n=10), depending on cilta-cel manufacturing availability. Participants in Group 1 will receive a maximum of 2 cycles of Dara-VRD induction therapy followed by apheresis and infusion of cilta-cel. Participants in Group 2 will undergo apheresis followed by 2 cycles of Dara-VRD induction therapy and cilta-cel infusion with the objective of evaluating changes in the quantity and quality of T cells collected.
###  Premature Closure of Fetal Ductus Arteriosus:

Avoid use of NSAIDs, including Dolobid, in pregnant women at about 30 weeks gestation and later. NSAIDs including Dolobid, increase the risk of premature closure of the fetal ductus arteriosus at approximately this gestational age.

###  Oligohydramnios/Neonatal Renal Impairment:

Use of NSAIDs, including Dolobid, at about 20 weeks gestation or later in pregnancy may cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation. Oligohydramnios is often, but not always, reversible with treatment discontinuation. Complications of prolonged oligohydramnios may, for example, include limb contractures and delayed lung maturation. In some postmarketing cases of impaired neonatal renal function, invasive procedures such as exchange transfusion or dialysis were required.

If NSAID treatment is necessary between about 20 weeks and 30 weeks gestation, limit Dolobid, use to the lowest effective dose and shortest duration possible. Consider ultrasound monitoring of amniotic fluid if Dolobid treatment extends beyond 48 hours. Discontinue Dolobid if oligohydramnios occurs and follow up according to clinical practice [see PRECAUTIONS; Pregnancy] .
In a 104-week carcinogenicity study with daily oral administration of pamidronate in rats, there was a positive dose response relationship for benign adrenal pheochromocytoma in males (P<0.00001). Although this condition was also observed in females, the incidence was not statistically significant. When the dose calculations were adjusted to account for the limited oral bioavailability of pamidronate in rats, systemic exposure with the lowest daily dose associated with adrenal pheochromocytoma resulted in systemic exposures that were similar to the systemic exposure achieved at the intended clinical dose. Adrenal pheochromocytoma was also observed in low numbers in the control animals and is considered a relatively common spontaneous neoplasm in the rat. Pamidronate given daily by oral administration was not carcinogenic in an 80-week study in mice.

Pamidronate was nonmutagenic in six mutagenicity assays, including: the Ames bacterial mutagenicity assay (with and without metabolic activation), nucleus-anomaly test, sister-chromatid-exchange study, point-mutation test, and micronucleus test in the rat.

In rats, decreased fertility occurred in first-generation offspring of parents who had received 150 mg/kg of pamidronate orally; however, this occurred only when animals were mated with members of the same dose group. Pamidronate has not been administered intravenously in such a study.
Qualified inpatients will be enrolled and randomly given a flexible-dose regimen of Risperidone or Zotepine. Autonomic dysfunction is checked using analysis of heart rate variability before any active drug given. The initial starting dose of each drug is 1mg(risperidone) or 50 mg(zotepine) once a day. The dosage was increased depending on the status of delirium during the first 7 days and will be adjusted until patients are maximally stabilized or until intolerable adverse events necessitated cessation. Risperidone or zotepine will be tapered off in 10 days when patients are considered stable. No concomitant psychotropic medications will be used during the study except for lorazepam, which are given for severe agitation or insomnia . Patients are assessed by another rater blinded to active drug at the time of enrollment, the subsequent 12, 24,and then assessed daily until discharge. The study period is estimated to be around 12 months upon the designed number of subjects are reached.
Diarrhea has been reported during treatment with lapatinib [see Adverse Reactions(6.1)].The diarrhea may be severe, and deaths have been reported. Diarrhea generally occurs early during treatment with lapatinib, with almost half of those patients with diarrhea first experiencing it within 6 days. This usually lasts 4 to 5 days. Lapatinib-induced diarrhea is usually low-grade, with severe diarrhea of NCI CTCAE Grades 3 and 4 occurring in less than 10% and less than 1% of patients, respectively. Early identification and intervention is critical for the optimal management of diarrhea. Patients should be instructed to report any change in bowel patterns immediately. Prompt treatment of diarrhea with anti-diarrheal agents (such as loperamide) after the first unformed stool is recommended. Severe cases of diarrhea may require administration of oral or intravenous electrolytes and fluids, use of antibiotics, such as fluoroquinolones (especially if diarrhea is persistent beyond 24 hours, there is fever, or Grade 3 or 4 neutropenia), and interruption or discontinuation of therapy with lapatinib [see Dosage and Administration (2.2)].
70 participants (above 18 years of age) will be recruited from the post-COVID recovery clinic at the Beilinson Hospital, in the Rabin Medical Center (RMC). Only patients previously diagnosed using reverse transcription-polymerase chain reaction (RT-PCR), and that had no neurological or psychiatric disease prior to the COVID-19 episode, will be included. To avoid the risk of measuring adverse effects of lack of oxygen and/or artificial respiration procedures, COVID-19 patients who suffered from severe acute disease (according to World Health Organization criteria) will be excluded from participation. All potential participants will be given a detailed explanation about the research goals and procedure and they will all be asked to sign an institutional review board (IRB) consent form. Two groups, matched for age (5± years), will be examined: 35 case study patients: convalescents who report suffering from cognitive/emotional decline after recovering from COVID-19, and 35 control cases: convalescents with no cognitive/emotional complaints Participants will undergo: (1) An evaluation of COVID-19-related symptoms such as fatigue, post-exertional malaise, dizziness, etc. (2) A comprehensive evaluation of behavioral measures (e.g., hearing, vision, olfaction, sleep, social engagement) (3) A short validated neuropsychological evaluation, of multiple cognitive domains, with an emphasis on the memory domain; motivational factors will also be taken into account using performance validity tests (4) A thorough well-being and emotional state assessment, including the evaluation of mood disturbance and quality of life. The assessment will involve both self-report and cognitive tasks, previously associated with psychopathology. By recruiting a heterogeneous cohort in terms of symptom severity, the investigators will be able to test possible correlations between the emotional and cognitive impairments. In addition to the above-mentioned evaluations, a subgroup of participants will undergo either magnetic resonance imaging (MRI) or fluorodeoxyglucose (FDG)-positron emission tomography (PET)-computed tomography (CT), with the aim of clarifying the neural mechanisms underlying the neurologically-related symptoms.
Losing either type of cochlear sensory hair cells leads to hearing impairment. Inner hair cells act as primary mechanoelectrical transducers, while outer hair cells enhance sound-induced vibrations within the organ of Corti. Established inner ear damage models, such as systemic administration of ototoxic aminoglycosides, yield inconsistent and variable hair cell death in mice. Overcoming this limitation, we developed a method involving surgical delivery of a hyperosmotic sisomicin solution into the posterior semicircular canal of adult mice. This procedure induced rapid and synchronous apoptotic demise of outer hair cells within 14 h, leading to irreversible hearing loss. The combination of sisomicin and hyperosmotic stress caused consistent and synergistic ototoxic damage. Inner hair cells remained until three days post-treatment, after which deterioration in structure and number was observed, culminating in a complete hair cell loss by day seven. This robust animal model provides a valuable tool for otoregenerative research, facilitating single-cell and omics-based studies toward exploring preclinical therapeutic strategies.
This is an observational retrospective multicentric cohort study. The primary outcome of the study is the global Progression-free survival (PFS) adjusted for the risk factors considered. In a subgroup of patients only previously enrolled in San Raffaele Hospital that were included in the BIO-PANCREAS study (approval number INT/96/2021, a local monocentric protocol in which blood and/or Endoscopic UltraSound-Fine Needle Aspiration (EUS-FNA) derived samples are collected for further molecular analyses), the trascriptome signature will also be investigated as potential biomarker of disease behavior. Retrospective enrolment will be performed from January 2015 to March 2023. As for the primary aim, patients' and tumours' related variables will be investigated as explanatory variables for the outcome "time to progression", hence this analysis will allow a response to the clinical question of whether these factors have an influence on tumour behavior under treatment. As for the subgroup analysis (analysis of trascriptome signatures), again, this will be investigated to test whether there is a signature able to discriminate different responses to treatment.
Polypeptides having spasmolytic activity are obtained from animal organs of lymphoidal structure e.g. lymph ganglions of oxen or sheep or calf or lamb thymus, by hydrolysing the comminuted organs to a broth by warming with an aqueous solution of a protease e.g. papain, heating the broth to destroy the enzyme, clarifying the broth and fractionally precipitating the polypeptide from the clarified broth with alcohol, the active material being recovered from the product precipitated with the greatest concentration of alcohol.  The hydrolysis may be carried out at 60 DEG  C. for 15 minutes at a pH of 7.0.  After filtration, the clarified broth may be treated with an equal volume of 90% ethanol, the precipitate discarded, and seven volumes of absolute ethanol added to precipitate the polypeptide. The crude polypeptide may be purified by solution in acetic acid and further precipitation with ether.  Further purification may be by dialysis against water or chromatographic adsorption on an aluminium oxide and/or cellulose column.
Tissue samples are collected from patients. Tissue samples are analyzed by immunohistochemistry (Ki67, CK5/6, EGFR, ER) and fluorescence in situ hybridization (FISH).
Excisional haemorrhoidectomy is the gold standard for operating haemorrhoids, but it is accompanied by a significant problem: postoperative pain. Several strategies have been adopted to minimize this condition. Oral metronidazole has been proven to reduce postoperative pain but with some complications. This systematic review was conducted to investigate the effects and general efficacy of topical metronidazole administration and to evaluate its potential superiority over the oral formula. A systematic review of the literature was carried out. Randomized controlled trials published until September 2023 on PubMed, Central, and Web of Science were considered. The primary outcome considered was postoperative pain, which was evaluated using visual analogue scores. The secondary outcomes were analgesic use, return to work, and complications. Six randomized controlled trials were included, with a total of 536 patients. Topical metronidazole was compared with placebo in two studies, with oral formula in three studies, and with placebo and oral administration in one study. Topical metronidazole was found to be effective for treating postoperative pain when compared to a placebo but had no significant advantage over the oral formula. No complications were reported in the studies. Topical and oral metronidazole are effective solutions for postoperative pain after excisional haemorrhoidectomy. No superiority was demonstrated based on the route of administration, and complications were marginal for both formulas. Further studies are required to determine the best metronidazole solution.
The proposed study comparing the effects of conventional pelvic floor training versus a comprehensive rehabilitation program on stress urinary incontinence (SUI) among perimenopausal women holds significant rationale and importance. Given the prevalence and impact of SUI on the quality of life of perimenopausal women, investigating the comparative efficacy of these interventions is crucial for informing evidence-based clinical practice. The study aims to provide insights into the most effective management strategies for SUI in this population, potentially leading to improved treatment outcomes, enhanced quality of life, and reduced healthcare burden associated with this common condition. By addressing this research gap, the study has the potential to significantly benefit both individual patients and the broader healthcare system.

This will be a randomized controlled trial. Non probability sampling technique will be used.The data collection procedure begins with the recruitment phase, potential participants meeting the study's criteria will be identified and provided with detailed information about the research aims and procedures. Once recruited, participants will undergo a screening process to confirm their eligibility, including assessments such as medical history reviews and diagnostic tests. After obtaining informed consent, baseline assessments will be conducted to establish the participants' initial status regarding urinary symptoms and quality of life. Following randomization into either the conventional pelvic floor training or comprehensive rehabilitation program group, participants will receive their assigned interventions of three weekly sessions for eight weeks.
This group will receive motor training concurrent with 20 minutes of either sham or active tDCS. Sham tDCS will be a 30-second ramp up from 0 to 2 milliamps (MA), then a 30-second ramp-down from 2 mA to 0 mA. The next 18 minutes will have no stimulation (0 mA), starting at minute 19 with 30-second ramp up from 0 to 2 milliamps (MA), then a 30-second ramp-down from 2 mA to 0 mA. Active tDCS will ramp up to 2 mA in the first 30 seconds, then stay at 2 mA for 19 minutes, then ramp down to 0 mA.
An improved sunscreen protection and insect repellent combination composition having an SPF factor of about 2 to about 50 and further having an unexpected, unusually long efficacy period when used in rainy conditions or prolonged periods of high humidity, such as in a tropical or sub-tropical rain forests, or the like, and after the wearer has been underwater. The composition forms a stable emulsion lotion that is easy to store. No special precautions are required by the person who applies the lotion. The composition includes a sunscreen agent, an insect repellent, an emulsifying agent, and a film former, all in an aqueous solvent. The composition forms a thin film on the skin, but it is non-greasy to the touch. The lotion is easily removed by scrubbing with soap and water.
PURPOSE: Surgical voice restoration (SVR) is associated with improved patient quality of life following laryngectomy. This study aims to determine the impact of the COVID-19 pandemic on patients with SVR and analyse the complications in this cohort of patients.
METHOD: A retrospective review of all patients with SVR at a single tertiary ear, nose, and throat (ENT) unit in the UK for 12 months during the COVID-19 pandemic, with comparison to the preceding 12 months. A survey was also administered to assess patients' experiences during the pandemic.
RESULT: Thirty-six patients were included in this study. During the pandemic period, 19.5% (n = 7) patients had significant complications, with five patients needing surgery to restore speech. In the 12 months pre-pandemic, 13.5% (n = 5) had significant complications, although none required surgery to restore speech. Six patients (19.4%) felt these complications were avoidable in normal circumstances. Further, 30.5% (n = 11) of patients reported a delay in seeking medical attention due to concerns about their vulnerability to COVID-19.
CONCLUSION: The COVID-19 pandemic has had an impact on many patients with SVR. This has resulted in a large proportion of patients experiencing delayed care, a loss of voice, a need for further surgical intervention, and negative impacts on their quality of life.
Anti-SIRPα antibodies, including multi-specific anti-SIRPα antibodies, are provided, as are related compositions and methods. The antibodies of the disclosure bind to SIRPα and can block the interaction of CD47 on one cell with SIRPα on a phagocytic cell. Antibodies that are bispecific for SIRPα and a second antigen are termed Bi-specific Macrophage Enhancing (BiME) antibodies and have emergent properties. The subject anti SIRPα antibodies find use in various therapeutic methods. Embodiments of the disclosure include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the anti-SIRPα antibodies; and cell lines that produce the antibodies. Also provided are amino acid sequences of exemplary anti-SIRPα antibodies.
FIELD: virology, veterinary science. SUBSTANCE: invention provides preparing vaccine for prophylaxisand control of diseases in animals including pseudorabies virus. Vaccine is useful against Aujeszky's diseases (pseudorabies) and other diseases in animals if mutation is the insertion that contains heterologous gene encoding antigen corresponding to this animal disease. Pseudorabies virus can carry additionally at least a single mutation in one of its other genes, for example, gene gp 63 or gene g1. This virus can not transferred from vaccinated to nonvaccinated animals. Attenuated virus can be administrated by intranasal route that provides the most effective prophylaxis of animal. EFFECT: mutant indicated above, enhanced effectiveness of vaccine. 4 cl, 3 tbl, 3 dwg, 6 ex